Alcon Inc. reports developments in eye care through its Surgical and Vision Care businesses. Company news commonly covers quarterly results, constant-currency sales trends, product-launch momentum and portfolio updates across cataract and vitreoretinal surgical systems, intraocular lenses, contact lenses, lens-care products and ocular health.
Recurring updates also include launches and milestones for products such as Clareon, PanOptix, Vivity, TOTAL30, Precision7, Tryptyr and Unity, along with annual general meeting items, board elections, compensation votes, dividends, share repurchase authorizations, acquisitions, integration costs, R&D spending and other governance or capital-allocation actions.
Alcon (NYSE:ALC), the global eye care leader, announced its participation in the 37th Asia-Pacific Association of Cataract and Refractive Surgeons (APACRS) Annual Meeting in Ahmedabad, India from August 21-23, 2025. The company will showcase four symposia, present 10 medical affairs scientific exchange presentations, and feature a hands-on experience zone.
Key highlights include new data on Vivity®, an Extended Depth of Focus (EDOF) intraocular lens, supported by over 10 clinical studies involving more than 700 patients. The company will also present research on cataract surgery performed at physiologic IOP in patients with diabetic retinopathy. Additionally, Alcon will officially introduce UNITY VCS (Vitreoretinal Cataract System) and UNITY CS (Cataract System), their next-generation Phaco/Vit platform, to the Indian market.
Alcon (SIX/NYSE: ALC) has entered into a definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) for $28 per share in cash, representing a total equity value of approximately $1.5 billion. The deal offers a 59% premium to STAAR's 90-day VWAP.
The acquisition includes STAAR's EVO family of Implantable Collamer® Lenses (ICL), which provides vision correction for moderate to high myopia patients. This strategic move enhances Alcon's surgical vision correction portfolio, particularly targeting the growing myopia market, expected to affect 50% of the world's population by 2050.
The transaction is expected to close within 6-12 months, subject to regulatory and STAAR shareholder approval, and become earnings accretive in year two. Alcon plans to finance the acquisition through short- and long-term credit facilities.
Alcon (NYSE:ALC) has received Health Canada approval for its UNITY® Vitreoretinal Cataract System (VCS), marking the first innovation from its Unity portfolio. The breakthrough surgical technology combines vitreoretinal and cataract surgical capabilities in one integrated platform.
The system delivers significant improvements over Alcon's current CONSTELLATION® and CENTURION® systems, featuring up to 2x faster nucleus removal with 40% less energy, and the world's fastest vitrectomy probe at 30,000 cuts per minute. The platform includes a novel phacoemulsification modality and a first-of-its-kind phaco handpiece that estimates incision site temperature.
Following successful testing with over 200 surgeons from 30+ countries, Unity VCS is scheduled for commercial launch in early 2026.
Alcon (SIX/NYSE: ALC) announced its intention to acquire LumiThera, Inc. and its photobiomodulation (PBM) device for treating early and intermediate dry Age-Related Macular Degeneration (AMD). The PBM device, which received FDA authorization in November 2024 and CE Mark in November 2018, is the first technology demonstrating meaningful visual improvement in dry AMD patients over two years of treatment.
The pivotal LIGHTSITE III study showed significant results: 88% of patients maintained or gained vision, and 64% gained at least one line of visual acuity. The device is currently available in Europe, Latin America, Singapore, the UK, and the US. The acquisition, excluding LumiThera's diagnostic devices, is expected to close in Q3 2025, subject to customary conditions and shareholder approval.
Alcon (NYSE:ALC), the global eye care leader, has achieved certification as a Top Employer in Canada for 2025 by the Top Employers Institute. The recognition highlights Alcon Canada's excellence in key areas including People Strategy, Career Development, Rewards and Recognition, Purpose and Values, and Diversity & Inclusion.
The company's strengths include its comprehensive learning programs, leadership development initiatives, and commitment to sustainability, aiming for carbon neutrality by 2030. Alcon Canada's Head Office maintains ISO 14001:2015 Environmental Management System certification and demonstrates strong ethical business practices, including compliance with the Accessibility for Ontarians with Disabilities Act.
Alcon (NYSE: ALC) has received FDA approval for TRYPTYR (acoltremon ophthalmic solution) 0.003%, a first-in-class treatment for Dry Eye Disease (DED). The drug, which works as a TRPM8 receptor agonist, demonstrated significant efficacy in Phase 3 trials involving over 930 patients. Up to four times more TRYPTYR patients experienced increased natural tear production compared to the control group, with results visible as early as Day 1.
The treatment, administered as one drop per eye twice daily, addresses a significant market need, as approximately 38 million Americans suffer from DED, with less than 10% receiving prescription treatment. Alcon plans to launch TRYPTYR in the U.S. during Q3 2025.
[ "First-in-class TRPM8 receptor agonist showing rapid efficacy as early as Day 1", "Strong Phase 3 trial results with up to 4x more patients showing improved tear production vs. placebo", "Addresses large untapped market of 38 million U.S. patients with DED", "First prescription pharmaceutical treatment approval since Alcon became independent" ]Alcon has launched the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS), introducing breakthrough technologies for eye surgery. The platform features HYPERVIT 30K, the world's fastest vitrectomy probe at 30,000 cuts per minute, and UNITY 4D Phaco technology that delivers up to 2X faster nucleus removal with 41% less energy impact.
Key innovations include the UNITY Intelligent Fluidics system, UNITY 27 Gauge Portfolio with Dynamic Stiffener technology, and UNITY TetraSpot illuminated laser probe that reduces laser application time by up to three times. The system also features UNITY Intelligent Sentry, reducing post-occlusion surge volumes by 44%.
The product will begin shipping to Australia, Europe, Japan, and the U.S. from May onwards, with other markets following in Q3 2025 pending regulatory approvals.